- name: aki_risk_factors
  type: guideline
  keywords:
  - aki
  - acute kidney injury
  - risk factors
  - aki risk
  - nephrotoxic
  - renal injury risk
  - kidney injury risk
  content: 'Acute Kidney Injury (AKI) Risk Factors:


    Patient Risk Factors:

    1. Advanced age (>65 years)

    2. Pre-existing CKD (baseline creatinine elevation or reduced GFR)

    3. Diabetes mellitus

    4. Hypertension

    5. Heart failure (especially acute decompensated)

    6. Liver disease or cirrhosis

    7. Sepsis or systemic infection

    8. Hypovolemia or dehydration

    9. Previous episodes of AKI


    Medication-Related Risk Factors (Nephrotoxins):

    1. NSAIDs (ibuprofen, naproxen, ketorolac)

    2. ACE inhibitors and ARBs (especially with volume depletion)

    3. Aminoglycosides (gentamicin, tobramycin, amikacin)

    4. Vancomycin (especially high trough levels)

    5. Amphotericin B

    6. Contrast agents (IV contrast for CT scans, angiography)

    7. Calcineurin inhibitors (tacrolimus, cyclosporine)

    8. Diuretics (can cause pre-renal AKI if volume depleted)

    9. Chemotherapy agents (cisplatin, methotrexate)


    Clinical Situations with High AKI Risk:

    1. Major surgery (cardiac, vascular, abdominal)

    2. Critical illness/ICU admission

    3. Severe burns

    4. Rhabdomyolysis (elevated CK)

    5. Tumor lysis syndrome

    6. Shock states (septic, cardiogenic, hypovolemic)

    7. Obstruction (urinary retention, kidney stones, prostatic hypertrophy)


    Prevention Strategies:

    - Maintain adequate hydration

    - Avoid nephrotoxic medications when possible

    - Monitor creatinine closely in high-risk patients

    - Adjust medication doses for renal function

    - Prompt treatment of infections and hemodynamic instability

    - Pre-hydration before contrast procedures


    Source: KDIGO AKI Guidelines; Clinical practice recommendations'
  source: KDIGO AKI Guidelines and clinical literature
  relevance_score: 1.0
- id: sepsis_criteria
  type: diagnostic_criteria
  name: Sepsis - Sepsis-3 Definition and Management
  content: "SEPSIS-3 DEFINITION (2016):\n\nDEFINITION:\n- Life-threatening organ dysfunction\
    \ caused by dysregulated host response to infection\n- Requires: (1) Suspected\
    \ or confirmed infection, PLUS (2) SOFA score increase ≥2 points\n\nqSOFA (Quick\
    \ SOFA) - Bedside Screening:\n- Altered mental status (GCS <15)\n- Systolic BP\
    \ ≤100 mmHg\n- Respiratory rate ≥22/min\n≥2 criteria: High risk for poor outcome,\
    \ prompt assessment needed\n\nSOFA SCORE (Sequential Organ Failure Assessment):\n\
    - Respiration: PaO2/FiO2 ratio\n- Coagulation: Platelets\n- Liver: Bilirubin\n\
    - Cardiovascular: MAP and vasopressors\n- CNS: Glasgow Coma Scale\n- Renal: Creatinine\
    \ or urine output\nScore 0-24; increase ≥2 = organ dysfunction\n\nSEPTIC SHOCK:\n\
    - Sepsis + persisting hypotension requiring vasopressors (MAP ≥65 mmHg)\n- AND\
    \ lactate >2 mmol/L despite adequate fluid resuscitation\n- Mortality >40%\n\n\
    DIAGNOSTIC WORKUP:\n- Blood cultures (×2 sets before antibiotics)\n- Lactate level\n\
    - CBC, CMP, coagulation studies\n- Source identification: Urinalysis, CXR, imaging\
    \ as indicated\n\nMANAGEMENT (Surviving Sepsis Campaign):\n1. HOUR-1 BUNDLE:\n\
    \   - Measure lactate (remeasure if >2 mmol/L)\n   - Obtain blood cultures before\
    \ antibiotics\n   - Administer broad-spectrum antibiotics\n   - Begin rapid fluid\
    \ resuscitation (30 mL/kg crystalloid if hypotensive/lactate ≥4)\n   - Apply vasopressors\
    \ if hypotensive during/after fluid resuscitation (MAP ≥65)\n\n2. SOURCE CONTROL:\n\
    \   - Identify and remove infection source within 12h if possible\n\n3. ADDITIONAL\
    \ INTERVENTIONS:\n   - Norepinephrine first-line vasopressor\n   - Stress-dose\
    \ steroids if refractory shock\n   - Avoid bicarbonate for pH ≥7.15\n   - Restrictive\
    \ transfusion strategy (Hgb <7 g/dL)\n\nPROGNOSIS:\n- Sepsis mortality: 10-20%\n\
    - Septic shock mortality: 40-50%"
  metadata:
    category: infectious
    diagnosis: sepsis
    priority: CRITICAL
    source: Sepsis-3 Definitions, Surviving Sepsis Campaign 2021
- id: extra_approach_001
  type: methodology
  content: 'Clinical Annotation Systematic Approach: (1) Read entire clinical record
    first for overview. (2) Identify primary diagnosis and expected findings. (3)
    Extract vital signs with trends (admission vs peak vs discharge). (4) Extract
    all abnormal lab values with clinical significance. (5) Review imaging systematically
    - chest X-ray for infiltrates/effusions/cardiomegaly, CT for specific findings.
    (6) Note medications as diagnostic clues - antibiotics suggest infection, diuretics
    suggest fluid overload, vasopressors suggest shock. (7) Extract temporal relationships
    - symptom onset, progression, hospital course. (8) Identify severity indicators
    - ICU admission, mechanical ventilation, vasopressor requirement, dialysis. (9)
    Note pertinent negatives - absence of expected findings. (10) Link evidence to
    pathophysiology.'
  metadata:
    category: general
    priority: HIGH
    subcategory: annotation_methodology
  created_at: '2025-11-10T00:00:00'
  name: Systematic Clinical Annotation Approach
- name: renal_replacement_therapy_indications
  type: guideline
  keywords:
  - dialysis
  - rrt
  - renal replacement therapy
  - hemodialysis
  - continuous renal replacement therapy
  - crrt
  - peritoneal dialysis
  - dialysis indication
  - aki dialysis
  content: "Renal Replacement Therapy (RRT) Indications:\n\nEmergent Indications (AEIOU\
    \ mnemonic):\nA - Acidosis: Severe metabolic acidosis (pH <7.1) refractory to\
    \ medical management\nE - Electrolytes: Life-threatening hyperkalemia (K+ >6.5\
    \ mEq/L with ECG changes) unresponsive to medical therapy\nI - Ingestions/Intoxications:\
    \ Certain toxins (methanol, ethylene glycol, lithium, salicylates)\nO - Fluid\
    \ overload: Pulmonary edema unresponsive to diuretics\nU - Uremia: Uremic complications\
    \ (pericarditis, encephalopathy, bleeding)\n\nAdditional Indications:\n1. AKI\
    \ Stage 3 with:\n   - Oliguria/anuria not responding to fluid resuscitation\n\
    \   - Uremia (BUN >100 mg/dL with symptoms)\n   - Severe azotemia\n\n2. Electrolyte\
    \ abnormalities:\n   - Severe hyperkalemia (K+ >6.5 mEq/L)\n   - Severe hyperphosphatemia\n\
    \   - Severe hypercalcemia or hypocalcemia\n\n3. Acid-base disorders:\n   - Severe\
    \ metabolic acidosis (pH <7.1 or HCO3 <10 mEq/L)\n\n4. Volume overload:\n   -\
    \ Pulmonary edema with hypoxemia\n   - Anasarca unresponsive to diuretics\n\n\
    5. Uremic symptoms:\n   - Encephalopathy\n   - Pericarditis\n   - Bleeding diathesis\n\
    \   - Nausea/vomiting from uremia\n\nRRT Modalities:\n\n1. Intermittent Hemodialysis\
    \ (IHD):\n   - Standard outpatient dialysis\n   - 3-4 hours per session\n   -\
    \ Hemodynamically stable patients\n\n2. Continuous Renal Replacement Therapy (CRRT):\n\
    \   - Continuous venovenous hemofiltration (CVVH)\n   - Continuous venovenous\
    \ hemodialysis (CVVHD)\n   - Preferred for hemodynamically unstable ICU patients\n\
    \   - Better fluid/electrolyte control\n   - Slower, more gradual treatment\n\n\
    3. Peritoneal Dialysis:\n   - Less common for acute AKI\n   - May be used in pediatrics\
    \ or resource-limited settings\n\nTiming Considerations:\n- Early initiation vs.\
    \ watchful waiting is debated\n- Most nephrologists initiate when emergent indications\
    \ present\n- Consider patient trajectory and likelihood of recovery\n\nSource:\
    \ KDIGO Guidelines; Nephrology clinical practice"
  source: KDIGO Guidelines and nephrology clinical practice
  relevance_score: 1.0
- id: extra_pneumonia_001
  type: diagnostic_criteria
  content: 'Pneumonia: Acute infection of lung parenchyma. Community-acquired (CAP)
    vs hospital-acquired (HAP) vs ventilator-associated (VAP). Clinical: fever, cough
    (productive), dyspnea, pleuritic chest pain, tachypnea. Exam: crackles, bronchial
    breath sounds, dullness to percussion, egophony. CXR: infiltrate/consolidation
    (lobar, multilobar, interstitial). Labs: leukocytosis or leukopenia, elevated
    procalcitonin. Sputum/blood cultures (before antibiotics). CURB-65 score for severity
    (Confusion, Urea >19, RR≥30, BP<90/60, age≥65): 0-1=outpatient, 2=inpatient, 3-5=ICU.
    PSI (Pneumonia Severity Index) also used. Organisms: S. pneumoniae (most common),
    H. influenzae, atypicals (Mycoplasma, Legionella, Chlamydia). Treatment: empiric
    antibiotics (β-lactam + macrolide or fluoroquinolone), adjust based on cultures.
    Complications: pleural effusion, empyema, sepsis, respiratory failure, death.'
  metadata:
    category: infectious_pulmonary
    diagnosis: pneumonia
    priority: HIGH
    icd9_codes:
    - '486'
    icd10_codes:
    - J189
  created_at: '2025-11-10T00:00:00'
  name: Pneumonia - Diagnosis & Severity Assessment
- id: hypertensive_heart_ckd_criteria
  type: diagnostic_criteria
  name: Hypertensive Heart and Chronic Kidney Disease
  content: "HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE:\n\nDEFINITION:\n- Combination\
    \ of hypertensive heart disease AND chronic kidney disease\n- ICD-10: I13.0 (with\
    \ heart failure), I13.1 (without HF), I13.2 (with HF and CKD stage 5/ESRD)\n\n\
    COMPONENTS:\n\n1. HYPERTENSIVE HEART DISEASE:\n   - Cardiac structural/functional\
    \ changes due to chronic hypertension\n   - LV hypertrophy (most common finding)\n\
    \   - Diastolic dysfunction → HFpEF\n   - May progress to systolic dysfunction\
    \ → HFrEF\n   - Coronary artery disease (accelerated atherosclerosis)\n\n2. CHRONIC\
    \ KIDNEY DISEASE:\n   - GFR <60 mL/min/1.73m² for ≥3 months\n   - OR kidney damage\
    \ (albuminuria, structural abnormality) for ≥3 months\n   \n   CKD Stages:\n \
    \  - Stage 1: GFR ≥90 with kidney damage\n   - Stage 2: GFR 60-89 with kidney\
    \ damage\n   - Stage 3a: GFR 45-59\n   - Stage 3b: GFR 30-44\n   - Stage 4: GFR\
    \ 15-29\n   - Stage 5: GFR <15 or on dialysis\n\nCARDIOVASCULAR-RENAL INTERACTION:\n\
    \nType 1 Cardiorenal Syndrome:\n- Acute cardiac dysfunction → acute kidney injury\n\
    - Example: Acute HF → reduced renal perfusion → AKI\n\nType 2 Cardiorenal Syndrome:\n\
    - Chronic cardiac dysfunction → progressive CKD\n- Example: Chronic HF → chronic\
    \ renal hypoperfusion → CKD\n\nType 4 Cardiorenal Syndrome:\n- Primary CKD → cardiac\
    \ disease\n- Mechanisms: Volume overload, anemia, electrolyte abnormalities, uremic\
    \ toxins\n\nType 5 Cardiorenal Syndrome:\n- Systemic disease affecting both (e.g.,\
    \ diabetes, hypertension)\n\nDIAGNOSTIC EVALUATION:\n\n1. CARDIAC:\n   - Echocardiogram:\
    \ LV mass, LVEF, diastolic function, wall thickness\n   - ECG: LVH (Sokolow-Lyon,\
    \ Cornell criteria)\n   - BNP/NT-proBNP (if HF symptoms)\n   - Coronary assessment\
    \ if angina\n\n2. RENAL:\n   - Serum creatinine, calculate eGFR (CKD-EPI equation)\n\
    \   - Urinalysis: Protein, albumin-to-creatinine ratio (ACR)\n   - Electrolytes:\
    \ K, bicarb, calcium, phosphate, PTH\n   - CBC: Anemia common in CKD\n   - Renal\
    \ ultrasound: Size, echogenicity, obstruction\n\n3. BLOOD PRESSURE:\n   - Ambulatory\
    \ BP monitoring (if suspected white coat or masked HTN)\n   - Home BP monitoring\n\
    \nBLOOD PRESSURE TARGETS:\n\nGeneral CKD:\n- <130/80 mmHg (ACC/AHA 2017)\n- <140/90\
    \ mmHg (KDIGO 2021, more conservative)\n\nCKD with albuminuria:\n- <130/80 mmHg\
    \ to reduce albuminuria and CV events\n\nDialysis:\n- Individualized, generally\
    \ <140/90 pre-dialysis\n\nTREATMENT:\n\n1. BLOOD PRESSURE CONTROL:\n   \n   First-line\
    \ (CKD with albuminuria or diabetes):\n   - ACE inhibitor OR ARB (not both)\n\
    \   - Reduces proteinuria, slows CKD progression\n   - Monitor: Cr may increase\
    \ up to 30% (acceptable), K\n   \n   Additional agents:\n   - Thiazide diuretic\
    \ (if GFR >30) or loop diuretic (if GFR <30)\n   - Calcium channel blocker (dihydropyridine)\n\
    \   - Beta-blocker (if HF, CAD, or post-MI)\n   \n   Avoid:\n   - NSAIDs (nephrotoxic,\
    \ worsen BP control)\n   - Mineralocorticoid receptor antagonists if K >5.0 or\
    \ GFR <30 (unless carefully monitored)\n\n2. HEART FAILURE MANAGEMENT:\n   - GDMT\
    \ for HFrEF: ACE-I/ARB/ARNI, beta-blocker, MRA, SGLT2i\n   - SGLT2 inhibitors:\
    \ Benefit in both HF and CKD (reduce progression)\n   - Diuretics for volume management\n\
    \   - Adjust doses for renal function\n\n3. CKD MANAGEMENT:\n   - Slow progression:\
    \ BP control, RAAS inhibition, SGLT2i\n   - Manage complications:\n     * Anemia:\
    \ ESA if Hgb <10, iron supplementation\n     * Bone disease: Phosphate binders,\
    \ vitamin D, manage PTH\n     * Acidosis: Sodium bicarbonate if bicarb <22\n \
    \    * Hyperkalemia: Dietary restriction, K-binders (patiromer, SZC)\n   - Diet:\
    \ Protein restriction (0.8 g/kg/day), sodium <2g/day, potassium restriction if\
    \ elevated\n   - Prepare for RRT if approaching stage 5\n\n4. CARDIOVASCULAR RISK\
    \ REDUCTION:\n   - Statin therapy (moderate-high intensity)\n   - Antiplatelet\
    \ if CAD (weigh bleeding risk)\n   - Lifestyle: Smoking cessation, weight loss,\
    \ exercise\n\nMONITORING:\n- Serum Cr, eGFR, electrolytes: Every 3-6 months (more\
    \ frequent if unstable)\n- Urine ACR: Annually\n- Echocardiogram: As clinically\
    \ indicated\n- BP: Home monitoring\n\nPROGNOSIS:\n- CKD is major CV risk factor\
    \ (equivalent to CAD)\n- Risk of CV death > risk of progression to ESRD in early\
    \ CKD\n- Combined heart and kidney disease: Significantly worse prognosis\n- Tight\
    \ BP control and RAAS inhibition reduce CV events and slow CKD progression"
  metadata:
    category: cardiovascular_renal
    diagnosis: hypertensive_heart_disease_with_ckd
    priority: HIGH
    source: KDIGO 2021, ACC/AHA HTN Guidelines 2017
- name: nephrotoxic_medications
  type: reference
  keywords:
  - nephrotoxic
  - nephrotoxicity
  - kidney damage
  - medication
  - drug induced
  - aki medication
  - renal toxicity
  - drug renal
  content: "Nephrotoxic Medications - Complete Reference:\n\n1. NSAIDs (Non-Steroidal\
    \ Anti-Inflammatory Drugs):\n   - Examples: Ibuprofen, naproxen, ketorolac, indomethacin,\
    \ diclofenac, celecoxib\n   - Mechanism: Inhibit prostaglandin synthesis → decreased\
    \ renal perfusion\n   - Risk: Acute tubular necrosis, interstitial nephritis,\
    \ papillary necrosis\n   - Higher risk with: Volume depletion, heart failure,\
    \ cirrhosis, pre-existing CKD\n\n2. ACE Inhibitors and ARBs:\n   - Examples: Lisinopril,\
    \ enalapril, losartan, valsartan\n   - Mechanism: Efferent arteriole dilation\
    \ → decreased GFR\n   - Risk: Acute decrease in GFR, hyperkalemia\n   - Avoid:\
    \ Bilateral renal artery stenosis, severe volume depletion\n\n3. Aminoglycosides:\n\
    \   - Examples: Gentamicin, tobramycin, amikacin\n   - Mechanism: Direct tubular\
    \ toxicity\n   - Risk: Dose and duration dependent\n   - Monitor: Trough levels,\
    \ creatinine\n\n4. Vancomycin:\n   - Mechanism: Direct tubular damage\n   - Risk:\
    \ Increased with high trough levels (>20 mg/L)\n   - Higher risk when combined\
    \ with other nephrotoxins\n\n5. Contrast Agents:\n   - Types: Iodinated contrast\
    \ (CT, angiography)\n   - Mechanism: Contrast-induced nephropathy (CIN)\n   -\
    \ Risk factors: Pre-existing CKD, diabetes, volume depletion, contrast volume\n\
    \   - Prevention: Pre-hydration with IV fluids\n\n6. Diuretics:\n   - Examples:\
    \ Furosemide, hydrochlorothiazide\n   - Mechanism: Volume depletion → pre-renal\
    \ AKI\n   - Risk: Excessive diuresis, electrolyte abnormalities\n\n7. Calcineurin\
    \ Inhibitors:\n   - Examples: Tacrolimus, cyclosporine\n   - Used in: Transplant\
    \ immunosuppression\n   - Mechanism: Vasoconstriction, chronic fibrosis\n   -\
    \ Monitor: Drug levels, creatinine\n\n8. Chemotherapy Agents:\n   - Cisplatin:\
    \ Direct tubular toxicity\n   - Methotrexate: Crystalline nephropathy\n   - Ifosfamide:\
    \ Tubular damage\n   - Prevention: Aggressive hydration, dose adjustment\n\n9.\
    \ Amphotericin B:\n   - Antifungal agent\n   - Mechanism: Direct tubular toxicity\n\
    \   - Risk: Dose dependent\n   - Liposomal forms less nephrotoxic\n\n10. Lithium:\n\
    \    - Used for: Bipolar disorder\n    - Mechanism: Chronic interstitial nephritis,\
    \ nephrogenic diabetes insipidus\n    - Monitor: Lithium levels, creatinine\n\n\
    11. Proton Pump Inhibitors (PPIs):\n    - Examples: Omeprazole, pantoprazole,\
    \ esomeprazole\n    - Mechanism: Acute interstitial nephritis\n    - Risk: Usually\
    \ after weeks to months of use\n\n12. Antivirals:\n    - Acyclovir: Crystalline\
    \ nephropathy\n    - Tenofovir: Tubular toxicity\n    - Cidofovir: Direct tubular\
    \ damage\n\nCombination Risks:\n- Triple whammy: NSAID + ACE-I/ARB + Diuretic\
    \ = very high AKI risk\n- Aminoglycoside + Vancomycin = synergistic nephrotoxicity\n\
    - Multiple nephrotoxins = cumulative risk\n\nPrevention Strategies:\n- Avoid nephrotoxins\
    \ in high-risk patients when possible\n- Maintain adequate hydration\n- Monitor\
    \ creatinine and electrolytes\n- Dose adjust for renal function\n- Use alternative\
    \ medications when available\n- Minimize duration of nephrotoxic drugs\n\nSource:\
    \ Clinical pharmacology and nephrology literature"
  source: Clinical pharmacology and nephrology references
  relevance_score: 1.0
- id: aortic_valve_disorders_criteria
  type: diagnostic_criteria
  name: Aortic Stenosis - Diagnosis and Management
  content: "AORTIC STENOSIS (AS):\n\nDEFINITION:\n- Narrowing of aortic valve orifice\n\
    - Obstruction to LV outflow\n\nETIOLOGY:\n- Degenerative/calcific (most common,\
    \ elderly)\n- Bicuspid aortic valve (younger patients)\n- Rheumatic (rare in developed\
    \ countries)\n\nCLASSIC TRIAD (Late symptoms):\n1. Exertional dyspnea (HF)\n2.\
    \ Angina (myocardial O2 supply-demand mismatch)\n3. Syncope (exertional, due to\
    \ fixed CO)\n\nPHYSICAL EXAM:\n- Crescendo-decrescendo systolic murmur\n- Radiates\
    \ to carotids\n- Diminished/delayed carotid upstrokes (pulsus parvus et tardus)\n\
    - Paradoxical splitting S2 (if severe)\n- S4 gallop\n\nECHOCARDIOGRAPHIC CRITERIA:\n\
    \nSeverity grading:\n\nMild AS:\n- Aortic jet velocity: 2.6-2.9 m/s\n- Mean gradient:\
    \ <20 mmHg\n- Valve area: >1.5 cm²\n\nModerate AS:\n- Velocity: 3.0-3.9 m/s\n\
    - Mean gradient: 20-39 mmHg\n- Valve area: 1.0-1.5 cm²\n\nSevere AS:\n- Velocity:\
    \ ≥4.0 m/s\n- Mean gradient: ≥40 mmHg\n- Valve area: <1.0 cm² (or indexed area\
    \ <0.6 cm²/m²)\n\nVery Severe AS:\n- Velocity: ≥5.0 m/s\n- Mean gradient: ≥60\
    \ mmHg\n- Valve area: <0.75 cm²\n\nAdditional assessment:\n- LV function (LVEF)\n\
    - LV hypertrophy\n- Degree of calcification\n\nSTAGING (ACC/AHA 2020):\n\nStage\
    \ A: At risk\n- Bicuspid AoV, sclerosis\n- Asymptomatic, normal hemodynamics\n\
    \nStage B: Progressive\n- Mild-moderate AS\n- Asymptomatic\n\nStage C: Asymptomatic\
    \ severe AS\n- C1: LVEF >50%\n- C2: LVEF <50%\n\nStage D: Symptomatic severe AS\n\
    - D1: High gradient (≥40 mmHg)\n- D2: Low-flow/low-gradient with reduced LVEF\n\
    - D3: Low-flow/low-gradient with normal LVEF (paradoxical)\n\nNATURAL HISTORY:\n\
    - Asymptomatic severe AS: 2-5 years to symptoms\n- Once symptoms: Survival 2-3\
    \ years without intervention\n- Sudden cardiac death: 1% per year if asymptomatic,\
    \ much higher if symptomatic\n\nINDICATIONS FOR INTERVENTION:\n\n1. Symptomatic\
    \ severe AS (Class I)\n2. Asymptomatic severe AS with:\n   - LVEF <50%\n   - Undergoing\
    \ other cardiac surgery\n   - Very severe AS (velocity ≥5 m/s)\n   - Rapid progression\
    \ (velocity increase ≥0.3 m/s/year)\n   - BNP >3× normal\n   - Abnormal exercise\
    \ test\n\nTREATMENT OPTIONS:\n\n1. SURGICAL AVR (SAVR):\n   - Mechanical valve\
    \ (requires lifelong anticoagulation)\n   - Bioprosthetic valve (no anticoagulation,\
    \ but limited durability 10-20 years)\n   - Indications: Low surgical risk, younger\
    \ age, other cardiac surgery needed\n\n2. TRANSCATHETER AVR (TAVR):\n   - Less\
    \ invasive, transfemoral or transapical approach\n   - Now approved for all risk\
    \ categories\n   - Preferred if high surgical risk, elderly >80\n   - Complications:\
    \ Vascular injury, stroke, paravalvular leak, conduction abnormalities (may need\
    \ PPM)\n\n3. BALLOON VALVULOPLASTY:\n   - Palliative only (high restenosis rate)\n\
    \   - Bridge to AVR or destination if not candidate\n\nMEDICAL MANAGEMENT:\n-\
    \ No medications slow AS progression\n- Treat hypertension cautiously (avoid aggressive\
    \ BP lowering)\n- Avoid strenuous activity if symptomatic severe AS\n- Serial\
    \ echo surveillance:\n  * Mild AS: Every 3-5 years\n  * Moderate AS: Every 1-2\
    \ years\n  * Severe asymptomatic: Every 6-12 months\n\nCOMPLICATIONS:\n- Heart\
    \ failure (most common)\n- Sudden cardiac death\n- Syncope\n- Gastrointestinal\
    \ bleeding (Heyde syndrome: AVMs + AS)\n- Endocarditis\n\nPROGNOSIS:\n- Excellent\
    \ after AVR/TAVR (30-day mortality 1-3% for SAVR, 1-2% for TAVR)\n- Poor without\
    \ intervention if symptomatic (50% mortality at 2 years)"
  metadata:
    category: cardiovascular
    diagnosis: aortic_valve_disorders
    priority: HIGH
    source: ACC/AHA Valvular Heart Disease Guidelines 2020
- id: aki_kdigo_criteria
  name: AKI KDIGO Criteria
  type: criteria
  content: 'Stage 1: SCr 1.5-1.9x baseline or ≥0.3 mg/dL increase, or UO <0.5 mL/kg/h
    for 6-12h. Stage 2: SCr 2-2.9x baseline, or UO <0.5 mL/kg/h for ≥12h. Stage 3:
    SCr ≥3x baseline or ≥4.0 mg/dL increase, or UO <0.3 mL/kg/h for ≥24h, or anuria
    ≥12h. Requires baseline SCr.'
  metadata:
    category: nephrology
    subcategory: aki
    priority: medium
  created_at: '2025-11-05T02:53:21.385691'
- id: pneumonia_criteria
  type: diagnostic_criteria
  name: Pneumonia - Community-Acquired Pneumonia (CAP) Guidelines
  content: 'COMMUNITY-ACQUIRED PNEUMONIA (CAP):


    DEFINITION:

    - Acute infection of lung parenchyma acquired outside healthcare setting

    - Develops >48 hours after hospital discharge


    CLINICAL PRESENTATION:

    - Symptoms: Cough (productive/non-productive), fever, dyspnea, pleuritic chest
    pain

    - Signs: Tachypnea, tachycardia, crackles, bronchial breath sounds, dullness to
    percussion


    DIAGNOSTIC CRITERIA:

    - Clinical signs/symptoms of pneumonia

    - Radiographic infiltrate (CXR or CT)


    COMMON PATHOGENS:

    - Streptococcus pneumoniae (most common)

    - Mycoplasma pneumoniae, Chlamydia pneumoniae (atypicals)

    - Haemophilus influenzae

    - Respiratory viruses (influenza, RSV, SARS-CoV-2)

    - Legionella pneumophila


    SEVERITY ASSESSMENT - CURB-65:

    - C: Confusion

    - U: Urea >19 mg/dL (BUN >19)

    - R: Respiratory rate ≥30/min

    - B: Blood pressure (SBP <90 or DBP ≤60)

    - 65: Age ≥65 years

    Score 0-1: Outpatient, 2: Inpatient, ≥3: ICU consideration


    PSI (Pneumonia Severity Index):

    - More complex, 20 variables

    - Classes I-V; I-II outpatient, III consider admission, IV-V inpatient


    WORKUP:

    - CXR (PA and lateral)

    - CBC, CMP

    - Blood cultures (if severe)

    - Sputum culture (if severe or MRSA/Pseudomonas risk)

    - Urinary antigen: Legionella, Pneumococcus (if severe)

    - Viral testing during flu season


    TREATMENT:

    Outpatient:

    - No comorbidities: Amoxicillin 1g TID OR doxycycline OR macrolide

    - With comorbidities: Amoxicillin-clavulanate + macrolide OR respiratory fluoroquinolone


    Inpatient (non-ICU):

    - Beta-lactam (ceftriaxone, ampicillin-sulbactam) + macrolide

    - OR respiratory fluoroquinolone monotherapy


    ICU:

    - Beta-lactam (ceftriaxone, cefotaxime) + azithromycin

    - OR beta-lactam + respiratory fluoroquinolone

    - Add vancomycin or linezolid if MRSA risk

    - Add antipseudomonal if risk factors


    DURATION: Minimum 5 days, afebrile 48-72h, clinically stable'
  metadata:
    category: infectious
    diagnosis: pneumonia
    priority: HIGH
    source: IDSA/ATS CAP Guidelines 2019
- id: aki_criteria
  type: diagnostic_criteria
  name: Acute Kidney Injury - KDIGO Classification
  content: "ACUTE KIDNEY INJURY (AKI) - KDIGO 2012:\n\nDEFINITION:\n- Increase in\
    \ serum creatinine ≥0.3 mg/dL within 48 hours\n- OR increase in creatinine ≥1.5×\
    \ baseline within 7 days\n- OR urine output <0.5 mL/kg/h for 6 hours\n\nKDIGO\
    \ STAGING:\nStage 1:\n- Cr 1.5-1.9× baseline OR ≥0.3 mg/dL increase\n- Urine output\
    \ <0.5 mL/kg/h for 6-12 hours\n\nStage 2:\n- Cr 2.0-2.9× baseline\n- Urine output\
    \ <0.5 mL/kg/h for ≥12 hours\n\nStage 3:\n- Cr 3.0× baseline OR ≥4.0 mg/dL OR\
    \ initiation of RRT\n- Urine output <0.3 mL/kg/h for ≥24 hours OR anuria ≥12 hours\n\
    \nCLASSIFICATION BY ETIOLOGY:\n\n1. PRE-RENAL (60-70%):\n   - Volume depletion,\
    \ hemorrhage, GI losses\n   - Decreased cardiac output (HF, MI)\n   - Medications\
    \ (NSAIDs, ACE-I, ARB)\n   - FENa <1%, BUN/Cr >20:1\n\n2. INTRINSIC RENAL (25-40%):\n\
    \   - Acute tubular necrosis (ATN) - most common\n   - Acute interstitial nephritis\
    \ (AIN)\n   - Glomerulonephritis\n   - Vascular (renal artery stenosis, thrombosis)\n\
    \   - FENa >2%, muddy brown casts (ATN), WBC casts (AIN)\n\n3. POST-RENAL (5-10%):\n\
    \   - Urinary tract obstruction\n   - Bladder outlet obstruction (BPH, neurogenic\
    \ bladder)\n   - Bilateral ureteral obstruction\n   - Hydronephrosis on ultrasound\n\
    \nWORKUP:\n- Serum creatinine, BUN, electrolytes\n- Urinalysis with microscopy\n\
    - Urine sodium, FENa = [(UNa × PCr)/(PNa × UCr)] × 100\n- Renal ultrasound (rule\
    \ out obstruction)\n- Consider: Autoimmune serologies, complement levels\n\nMANAGEMENT:\n\
    1. Identify and treat underlying cause\n2. Discontinue nephrotoxic medications\n\
    3. Optimize hemodynamics and volume status\n4. Avoid contrast and other nephrotoxins\n\
    5. Adjust medication doses for renal function\n6. Monitor fluid balance, daily\
    \ weights\n7. RRT indications: Refractory hyperkalemia, acidosis, volume overload,\
    \ uremic complications\n\nPROGNOSIS:\n- Stage 1: Generally reversible\n- Stage\
    \ 3: 50% progress to CKD, 25% require chronic dialysis"
  metadata:
    category: renal
    diagnosis: acute_kidney_injury
    priority: CRITICAL
    source: KDIGO AKI Guidelines 2012
- id: extra_uti_001
  type: diagnostic_criteria
  content: 'Urinary Tract Infection (UTI): Bacterial infection of urinary system.
    Lower (cystitis): dysuria, frequency, urgency, suprapubic pain, hematuria. Upper
    (pyelonephritis): fever, flank pain, CVA tenderness, nausea/vomiting. Diagnosis:
    UA shows WBC, bacteria, nitrites, leukocyte esterase; urine culture >10^5 CFU/mL
    (gold standard). Complicated UTI: male, pregnant, catheterized, anatomic abnormality,
    immunosuppressed, recent antibiotics, symptoms >7d. Organisms: E. coli (80%),
    Klebsiella, Proteus, Enterococcus, Pseudomonas (nosocomial). Treatment: uncomplicated
    cystitis (nitrofurantoin, TMP-SMX); pyelonephritis (fluoroquinolone or ceftriaxone);
    complicated (broad-spectrum, culture-guided). Complications: sepsis, renal abscess,
    chronic pyelonephritis. Risk factors: female, sexual activity, catheter, DM, obstruction.'
  metadata:
    category: infectious_genitourinary
    diagnosis: urinary_tract_infection
    priority: MODERATE
    icd9_codes:
    - '5990'
    icd10_codes:
    - N390
  created_at: '2025-11-10T00:00:00'
  name: UTI - Clinical Features & Management
- id: extra_aki_002
  type: diagnostic_criteria
  content: 'Acute Kidney Injury (AKI): Abrupt decline in renal function. KDIGO Criteria
    - Stage 1: Cr 1.5-1.9x baseline OR ≥0.3 mg/dL increase OR UOP <0.5 mL/kg/h x 6-12h.
    Stage 2: Cr 2-2.9x baseline OR UOP <0.5 mL/kg/h x ≥12h. Stage 3: Cr ≥3x baseline
    OR ≥4.0 mg/dL OR UOP <0.3 mL/kg/h x ≥24h OR anuria x 12h OR need for RRT. Etiology:
    Prerenal (60%: hypov olemia, hypotension, decreased CO, renal artery stenosis
    - responds to fluids, BUN/Cr >20:1, FENa <1%). Intrinsic renal (35%: ATN from
    ischemia/toxins, AIN, GN, vascular - muddy brown casts, FENa >2%). Postrenal (5%:
    obstruction - BPH, stones, tumor). Workup: basic metabolic panel, UA/micro, renal
    US. Complications: hyperkalemia, metabolic acidosis, volume overload, uremia.
    Treatment: treat cause, avoid nephrotoxins, dose-adjust meds, dialysis if indicated.'
  metadata:
    category: nephrology
    diagnosis: acute_kidney_injury
    priority: HIGH
    icd9_codes:
    - '5849'
    icd10_codes:
    - N179
    - N170
    - N171
    - N172
  created_at: '2025-11-10T00:00:00'
  name: AKI - KDIGO Staging & Etiology
- id: syncope_criteria
  type: diagnostic_criteria
  name: Syncope - Evaluation and Risk Stratification
  content: "SYNCOPE:\n\nDEFINITION:\n- Transient loss of consciousness (TLOC)\n- Rapid\
    \ onset, short duration, spontaneous complete recovery\n- Due to global cerebral\
    \ hypoperfusion\n\nCLASSIFICATION:\n\n1. REFLEX (NEURALLY-MEDIATED) SYNCOPE (60%):\n\
    \   - Vasovagal (most common): Emotional stress, pain, prolonged standing\n  \
    \ - Situational: Cough, micturition, defecation, post-exercise\n   - Carotid sinus\
    \ hypersensitivity\n   Mechanism: Inappropriate reflex → bradycardia/vasodilation\n\
    \n2. ORTHOSTATIC HYPOTENSION (15%):\n   - Volume depletion, medications (diuretics,\
    \ vasodilators)\n   - Autonomic failure (diabetes, Parkinson's, age)\n   - Defined:\
    \ SBP drop ≥20 mmHg or DBP ≥10 mmHg within 3min of standing\n\n3. CARDIAC SYNCOPE\
    \ (10-15%):\n   a. Arrhythmic:\n      - Bradycardia: Sinus node dysfunction, AV\
    \ block\n      - Tachycardia: VT, SVT, long QT, Brugada, WPW\n   b. Structural:\n\
    \      - Aortic stenosis, HCM, cardiac tamponade\n      - Pulmonary embolism,\
    \ pulmonary hypertension\n      - MI, aortic dissection\n   Highest mortality\
    \ risk\n\n4. UNKNOWN CAUSE (10-15%)\n\nEVALUATION:\n\nINITIAL (All patients):\n\
    1. History: Detailed description of event, prodrome, triggers, position, recovery\n\
    2. Physical exam: Orthostatic vital signs, cardiac exam, neurologic exam\n3. ECG:\
    \ Assess for arrhythmia, conduction disease, structural disease\n\nRED FLAGS (High-risk\
    \ features):\n- Age >60\n- No prodrome (sudden onset)\n- During exertion or supine\n\
    - Chest pain, dyspnea, palpitations\n- Family history sudden cardiac death\n-\
    \ ECG abnormalities: LBBB, bifascicular block, QTc >500ms, Brugada pattern, epsilon\
    \ waves, Q waves\n- Structural heart disease, HF\n- Severe anemia, electrolyte\
    \ abnormality\n\nADDITIONAL TESTING (Based on suspicion):\n\n1. CARDIAC:\n   -\
    \ Echocardiogram: If structural disease suspected\n   - Telemetry/Holter: If arrhythmia\
    \ suspected\n   - Event recorder (30-day): If recurrent unexplained\n   - Implantable\
    \ loop recorder: Recurrent unexplained, high-risk\n   - Exercise stress test:\
    \ If exertional syncope\n   - EP study: If high-risk ECG or known structural disease\n\
    \n2. ORTHOSTATIC:\n   - Tilt table test: If vasovagal suspected\n   - Autonomic\
    \ testing\n\n3. NEUROLOGIC (Rarely needed):\n   - CT/MRI brain: Only if focal\
    \ neurologic signs (not syncope)\n   - EEG: Only if concern for seizure\n   -\
    \ Carotid ultrasound: Not routinely indicated\n\nRISK STRATIFICATION - SAN FRANCISCO\
    \ SYNCOPE RULE:\nHigh risk if ANY:\n- History of heart failure (C)\n- Hematocrit\
    \ <30% (H)\n- Abnormal ECG (E)\n- Shortness of breath (S)\n- Systolic BP <90 mmHg\
    \ (T)\n\nAlternative: ROSE, OESIL, EGSYS scores\n\nMANAGEMENT:\n\n1. REFLEX SYNCOPE:\n\
    \   - Education, reassurance\n   - Avoid triggers, adequate hydration\n   - Physical\
    \ counterpressure maneuvers\n   - Midodrine or fludrocortisone if severe recurrent\n\
    \n2. ORTHOSTATIC HYPOTENSION:\n   - Adequate hydration (2-3L daily)\n   - Increase\
    \ salt intake\n   - Compression stockings\n   - Review/adjust medications\n  \
    \ - Midodrine, fludrocortisone, droxidopa\n\n3. CARDIAC SYNCOPE:\n   - Pacemaker:\
    \ Bradycardia, AV block\n   - ICD: Ventricular arrhythmias, high-risk cardiomyopathy\n\
    \   - Ablation: Supraventricular tachycardias\n   - Treat underlying structural\
    \ disease\n\n4. DRIVING RESTRICTIONS:\n   - Cardiac syncope: 3-6 months until\
    \ treated\n   - Single vasovagal: May resume after counseling\n   - Recurrent\
    \ unexplained: Until diagnosis/treatment\n\nPROGNOSIS:\n- Reflex/orthostatic:\
    \ Benign prognosis\n- Cardiac: 1-year mortality 20-40%\n- Overall recurrence:\
    \ 30% at 3 years"
  metadata:
    category: cardiovascular
    diagnosis: syncope
    priority: MEDIUM
    source: ESC Syncope Guidelines 2018, AHA/ACC/HRS
- name: kdigo_aki_stages
  type: guideline
  keywords:
  - aki
  - acute kidney injury
  - kdigo
  - creatinine
  - renal failure
  - kidney injury
  - aki stage
  - aki staging
  content: 'KDIGO Acute Kidney Injury (AKI) Staging Criteria:


    Definition: AKI is defined as any of the following:

    - Increase in serum creatinine by ≥0.3 mg/dL within 48 hours

    - Increase in serum creatinine to ≥1.5 times baseline within 7 days

    - Urine output <0.5 mL/kg/h for 6 hours


    Staging:


    Stage 1:

    - Serum creatinine: 1.5-1.9 times baseline OR ≥0.3 mg/dL increase

    - Urine output: <0.5 mL/kg/h for 6-12 hours


    Stage 2:

    - Serum creatinine: 2.0-2.9 times baseline

    - Urine output: <0.5 mL/kg/h for ≥12 hours


    Stage 3:

    - Serum creatinine: 3.0 times baseline OR increase to ≥4.0 mg/dL OR initiation
    of renal replacement therapy (RRT)

    - Urine output: <0.3 mL/kg/h for ≥24 hours OR anuria for ≥12 hours


    Baseline Creatinine:

    - Use the lowest creatinine value in the previous 7 days as baseline

    - If no prior creatinine available, may estimate using MDRD equation assuming
    baseline GFR 75 mL/min/1.73m²


    Clinical Significance:

    - Even Stage 1 AKI is associated with increased mortality and morbidity

    - AKI increases risk of progression to chronic kidney disease (CKD)

    - Early recognition allows for preventive interventions (fluid management, medication
    adjustment, nephrotoxin avoidance)


    Source: KDIGO Clinical Practice Guideline for Acute Kidney Injury (Kidney International
    Supplements 2012)'
  source: KDIGO AKI Guidelines 2012
  relevance_score: 1.0
- id: temporal_progression_initially_status
  type: pattern
  content: 'Temporal progression: ''initially [status], then [change], currently [status]''.
    Example: ''initially refusing all PO, then tolerating small volumes, currently
    taking 60% needs'''
  metadata:
    category: clinical_reasoning
    priority: medium
    subcategory: progression
  created_at: '2025-10-25T13:54:48.591486'
  name: 'Pattern: Temporal progression: ''initially [status...'
- id: uti_criteria
  type: diagnostic_criteria
  name: Urinary Tract Infection - Classification and Management
  content: "URINARY TRACT INFECTION (UTI):\n\nCLASSIFICATION:\n\n1. UNCOMPLICATED\
    \ CYSTITIS:\n   - Non-pregnant, premenopausal women\n   - No structural/functional\
    \ abnormalities\n   - Symptoms: Dysuria, frequency, urgency, suprapubic pain\n\
    \   - No fever or systemic symptoms\n\n2. COMPLICATED UTI:\n   - Male sex, pregnancy,\
    \ immunosuppression\n   - Structural/functional abnormalities (stones, catheter)\n\
    \   - Healthcare-associated\n   - Recent antibiotic use or resistant organisms\n\
    \n3. PYELONEPHRITIS:\n   - Upper tract infection\n   - Fever, flank pain, CVA\
    \ tenderness\n   - Nausea/vomiting\n   - May have lower tract symptoms\n\n4. ASYMPTOMATIC\
    \ BACTERIURIA:\n   - Positive culture without symptoms\n   - Treatment only in\
    \ pregnancy or before urologic procedures\n\nDIAGNOSTIC CRITERIA:\n\nUncomplicated\
    \ cystitis:\n- Symptoms alone sufficient in young women\n- Urinalysis: Pyuria,\
    \ bacteriuria, + nitrites, + leukocyte esterase\n- Culture not routinely needed\n\
    \nComplicated UTI/Pyelonephritis:\n- Urinalysis and urine culture\n- Culture >10^5\
    \ CFU/mL (or >10^3 if catheterized)\n- Blood cultures if septic\n- Imaging (ultrasound,\
    \ CT) if complicated course\n\nCOMMON PATHOGENS:\n- E. coli (75-95%)\n- Klebsiella,\
    \ Proteus, Enterococcus\n- Staphylococcus saprophyticus (young women)\n- Pseudomonas\
    \ (catheter-associated)\n\nTREATMENT:\n\nUncomplicated Cystitis (3-5 days):\n\
    - First-line: Nitrofurantoin 100mg BID × 5 days\n- Alternative: TMP-SMX DS BID\
    \ × 3 days (if local resistance <20%)\n- Second-line: Fosfomycin 3g single dose,\
    \ Beta-lactams\n\nComplicated UTI (7-14 days):\n- Fluoroquinolone (ciprofloxacin,\
    \ levofloxacin)\n- Ceftriaxone if severe\n- Tailor based on culture results\n\n\
    Pyelonephritis:\n- Outpatient (mild): Fluoroquinolone × 7 days or ceftriaxone\
    \ 1g IV then oral\n- Inpatient (moderate-severe): Ceftriaxone or fluoroquinolone\
    \ IV\n- Duration: 10-14 days total\n\nCatheter-Associated UTI (CAUTI):\n- Remove\
    \ or replace catheter if possible\n- 7-day treatment if prompt resolution\n- 10-14\
    \ days if delayed response\n\nPREVENTION:\n- Adequate hydration\n- Post-coital\
    \ voiding (women)\n- Avoid spermicides\n- Cranberry products (limited evidence)\n\
    - Prophylaxis if recurrent (≥2 UTIs in 6mo or ≥3 in 12mo)"
  metadata:
    category: infectious
    diagnosis: urinary_tract_infection
    priority: MEDIUM
    source: IDSA UTI Guidelines 2019
- id: extra_sepsis_001
  type: diagnostic_criteria
  content: 'Sepsis-3 Definition (2016): Sepsis is life-threatening organ dysfunction
    caused by a dysregulated host response to infection. Clinically defined as suspected
    or documented infection AND acute increase in Sequential Organ Failure Assessment
    (SOFA) score ≥2 points. Septic Shock is sepsis with persistent hypotension requiring
    vasopressors to maintain MAP ≥65 mmHg AND lactate >2 mmol/L despite adequate fluid
    resuscitation. Key indicators: fever/hypothermia, tachycardia, tachypnea, hypotension,
    altered mental status, elevated lactate, elevated WBC or leukopenia.'
  metadata:
    category: infectious_disease
    diagnosis: sepsis
    priority: CRITICAL
    icd9_codes:
    - 0389
    - '389'
    icd10_codes:
    - A419
  created_at: '2025-11-10T00:00:00'
  name: Sepsis-3 Diagnostic Criteria
- id: sepsis_recognition_qsofa
  name: Sepsis Recognition - qSOFA
  type: criteria
  content: 'Quick SOFA (≥2 indicates sepsis risk): Respiratory rate ≥22/min, Altered
    mentation (GCS <15), Systolic BP ≤100 mmHg. SIRS criteria (≥2): Temp >38°C or
    <36°C, HR >90, RR >20 or PaCO2 <32, WBC >12k or <4k or >10% bands. Early recognition
    critical for outcomes.'
  metadata:
    category: infectious_disease
    subcategory: sepsis
    priority: high
  created_at: '2025-11-05T02:53:21.384220'
- name: kdigo_ckd_stages
  type: guideline
  keywords:
  - ckd
  - chronic kidney disease
  - kdigo
  - egfr
  - renal insufficiency
  - kidney disease
  - ckd stage
  - chronic renal failure
  content: 'KDIGO Chronic Kidney Disease (CKD) Classification:


    CKD Definition:

    Kidney damage or GFR <60 mL/min/1.73m² for ≥3 months


    Stages Based on GFR:


    Stage 1: Normal or High GFR

    - GFR: ≥90 mL/min/1.73m²

    - Kidney damage present (albuminuria, hematuria, structural abnormality)

    - Description: Kidney damage with normal or increased GFR


    Stage 2: Mild Reduction in GFR

    - GFR: 60-89 mL/min/1.73m²

    - With kidney damage

    - Description: Mildly decreased GFR


    Stage 3a: Mild to Moderate Reduction

    - GFR: 45-59 mL/min/1.73m²

    - Description: Mildly to moderately decreased GFR

    - Clinical action: Evaluate and treat complications, slow progression


    Stage 3b: Moderate to Severe Reduction

    - GFR: 30-44 mL/min/1.73m²

    - Description: Moderately to severely decreased GFR

    - Clinical action: More intensive management of complications


    Stage 4: Severe Reduction

    - GFR: 15-29 mL/min/1.73m²

    - Description: Severely decreased GFR

    - Clinical action: Prepare for kidney replacement therapy


    Stage 5: Kidney Failure (ESRD)

    - GFR: <15 mL/min/1.73m²

    - Description: Kidney failure

    - Clinical action: Kidney replacement therapy if uremic


    Albuminuria Categories:

    A1 (Normal/Mild): <30 mg/g creatinine

    A2 (Moderate): 30-300 mg/g creatinine (microalbuminuria)

    A3 (Severe): >300 mg/g creatinine (macroalbuminuria)


    Risk Stratification (GFR + Albuminuria):

    - Green: Low risk (Stage 1-2, A1)

    - Yellow: Moderately increased risk

    - Orange: High risk

    - Red: Very high risk (Stage 4-5 or A3)


    Complications by Stage:

    Stage 3: Anemia, bone disease onset

    Stage 4: Hyperkalemia, metabolic acidosis, hyperphosphatemia

    Stage 5: Uremia, need for RRT consideration


    Source: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management
    of Chronic Kidney Disease'
  source: KDIGO CKD Guidelines 2012
  relevance_score: 1.0
